Lymphoma Clinical Trials in Shanghai, Shanghai Municipality
87 recruitingShanghai, Shanghai Municipality, China
Showing 1–20 of 87 trials
Recruiting
Phase 1
A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
MSD R&D (China) Co., Ltd.100 enrolled15 locationsNCT06189391
Recruiting
Phase 3
Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)
T-Cell Lymphoblastic Lymphoma
Children's Cancer Group, China200 enrolled2 locationsNCT05681260
Recruiting
Phase 3
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
BeOne Medicines630 enrolled155 locationsNCT06943872
Recruiting
Phase 3
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Mantle Cell LymphomaB-cell Lymphoma
BeOne Medicines300 enrolled149 locationsNCT06742996
Recruiting
Phase 3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Marginal Zone LymphomaRelapsed/Refractory Follicular Lymphoma
BeiGene780 enrolled277 locationsNCT05100862
Recruiting
Phase 2
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Hematologic MalignanciesWaldenstroms MacroglobulinaemiaNon-Hodgkins Lymphoma+1 more
Merck Sharp & Dohme LLC490 enrolled121 locationsNCT04728893
Recruiting
Phase 3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Diffuse Large B Cell Lymphoma
Merck Sharp & Dohme LLC1,046 enrolled246 locationsNCT06717347
Recruiting
T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NR
Peripheral T Cell Lymphoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine58 enrolled1 locationNCT07470996
Recruiting
Phase 2Phase 3
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Diffuse Large B Cell LymphomaDLBCL
Merck Sharp & Dohme LLC290 enrolled116 locationsNCT05139017
Recruiting
Phase 3
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Diffuse Large B Cell Lymphoma
Genmab360 enrolled177 locationsNCT06508658
Recruiting
Phase 3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Follicular Lymphoma ( FL)
Genmab1,095 enrolled265 locationsNCT06191744
Recruiting
Phase 3
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Refractory Follicular LymphomaFollicular LymphomaRelapsed/Refractory Follicular Lymphoma
Epizyme, Inc.612 enrolled229 locationsNCT04224493
Recruiting
Phase 3
Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy
Peripheral T Cell Lymphoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine68 enrolled1 locationNCT07414758
Recruiting
Phase 2
Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)
Diffuse Large B Cell Lymphoma
Sun Yat-sen University42 enrolled2 locationsNCT06517511
Recruiting
Phase 2Phase 3
A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma
Peripheral T Cell Lymphoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine40 enrolled1 locationNCT07389616
Recruiting
Phase 1Phase 2
Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.90 enrolled25 locationsNCT06829771
Recruiting
Phase 1Phase 2
Evaluate the Safety and Clinical Activity of HH2853
Advanced Solid TumorPeripheral T Cell LymphomaFL Lymphoma+1 more
Haihe Biopharma Co., Ltd.254 enrolled25 locationsNCT04390737
Recruiting
Phase 2
Unrelated Cord Blood Transplantation for EBV-associated Lymphoproliferative Disorders
Epstein-Barr Virus-associated Lymphoproliferative DiseasesChronic Active Epstein-Barr Virus InfectionEBV Associated Lymphoma+1 more
Fudan University80 enrolled2 locationsNCT07381738
Recruiting
Not Applicable
PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma
NK-T-Cell Lymphoma, Extranodal
Ruijin Hospital89 enrolled1 locationNCT06069830
Recruiting
T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-CR
Peripheral T Cell Lymphoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine160 enrolled1 locationNCT07353840